

PRESS RELEASE

Noida, Tuesday, May 12, 2015

JUBILANT LIFE SCIENCES – Q4 & FY 2015 RESULTS

The Board of Jubilant Life Sciences Limited, an integrated pharmaceuticals and life sciences company met today to approve financial results for the quarter and year ended March 31, 2015.

Commenting on the Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said:

“Sustained strong performance in our Radiopharmaceuticals business and normalisation of CMO operations supported revenue growth in the pharmaceuticals segment. In Life Science Ingredients, Nutritional Products and Fine Ingredients recorded healthy growth. Going forward, we expect the Pharmaceuticals segment to drive revenue growth with improvement in profitability in key businesses across both segments. We also expect the management consolidation to drive the businesses in a focussed manner to improve the operating performance. We will also continue our endeavours to strengthen the balance sheet.”

Q4 FY15 Highlights

- Consolidated revenue at Rs. 1,537 Crore
 - Pharmaceuticals revenue at Rs. 763 Crore, contributing 50% to the overall mix
 - LSI revenue at Rs. 774 Crore, contributing 50% to the overall mix
- International revenues at Rs. 1,115 Crore, contributing 73% to the overall mix
- EBITDA at Rs. 253 Crore and margins at 16.5%

FY15 Highlights

- Consolidated revenue at Rs. 5,826 Crore
 - Pharmaceuticals revenue at Rs. 2,682 Crore, contributing 46% to the overall mix
 - LSI revenue at Rs. 3,144 Crore, contributing 54% to the overall mix
- International revenues at Rs. 4,157 Crore, contributing 71% to the overall revenues
- EBITDA at Rs. 732 Crore with margins at 12.6%

Pharmaceuticals Segment Review

In Q4 FY2015, Income from Operations of the Pharmaceuticals segment was at Rs. 763 Crore, contributing 50% to the revenue mix. The segment EBITDA stood at Rs. 200 Crore, with EBITDA margins at 26.2%.



For FY2015, Income from Operations stood at Rs. 2,682 Crore, contributing 46% to the overall revenue mix. The segment EBITDA stood at Rs. 445 crore, with EBITDA margins at 16.6%.

Life Science Ingredients Segment Review

In Q4 FY2015, Income from Operations of the Life Science Ingredients segment stood at Rs. 774 Crore, contributing 50% to the revenue mix. The segment EBITDA stood at Rs 66 Crore, with EBITDA margins at 8.5%.

In FY2015, Income from Operations of the segment stood at Rs 3,144 crore, contributing 54% to the revenue mix. The segment EBITDA stood at Rs 322 crore, with EBITDA margins at 10.2%.

Geographical Overview

In Q4 FY2015, revenues from North America stood at Rs. 621 crore, contributing 40% to the overall revenues. Revenues from Europe and Japan stood at Rs. 284 crore, contributing 19% to the revenue mix. Domestic revenues grew 5% YoY and stood at Rs. 422 crore, thus contributing 27% to the overall mix. Revenues in ROW including China was at Rs. 209 crore, thus contributing 14% to the overall mix.

In FY2015, revenues from North America stood at Rs. 2,191 crore, contributing 38% to the revenue mix. Revenues from Europe and Japan stood at Rs. 1,175 crore, contributing 20% to the revenue mix. Revenues from ROW including China stood at Rs. 791 crore, contributing 14% to the revenue mix. Domestic revenues stood at Rs. 1,669 crore, up 13% YoY and contributing 29% to the revenue mix.

Outlook

In FY2016, revenue growth is expected to be driven by Pharmaceuticals segment primarily led by improved performance in Radiopharmaceuticals, normalization of our CMO business operations and growth in our generics business through new product and new market launches. Our Life Science Ingredients segment is expected to deliver better results due to improved operational efficiency and growth in Nutritional Products and Fine Ingredients businesses.

About Jubilant Life Sciences

Jubilant Life Sciences Limited is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. It also provides services in Contract Manufacturing of Sterile Injectables and Drug Discovery Solutions. The Company's strength lies in its unique offerings of Pharmaceuticals and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of around 6100 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com



For more information please contact:

For Investors

Ravi Agrawal
Jubilant Life Sciences Limited
Ph: +91-120 436 1002
E-mail: ravi_agrawal@jubl.com

Siddharth Rangnekar
CDR India
Ph: +91 22 6645 1209
E-mail: siddharth@cdr-india.com

Anupam Jain
Jubilant Life Sciences Limited
Ph: +91-120 436 1021
E-mail: anupam_jain@jubl.com

Karl Kolah
CDR India
Ph: +91 22 6645 1220
E-mail: karl@cdr-india.com

For Media

Neha Garg
Jubilant Life Sciences Limited
Ph: +91-120 436 1067
E-mail: neha_garg@jubl.com

Saurabh Gupta
Perfect Relations
Ph: +91 9818075578
E-mail: sgupta@perfectrelations.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.